JAMA Surgery:全美9年的腹部肿瘤切除术数据显示——术后输血率呈下降趋势

2016-01-14 QQduhp 译 MedSci原创

背景对手术病人,输血对他们而言或许具有救命的作用。然而异体输血后引起的相关免疫调节或许会增加围手术期患者死亡率增加及手术后患者预后不佳影响其生存质量。 目的该研究的目的在于探讨重大腹部肿瘤切除术输血率的发生率对临床结果的影响。 设计该研究是以人群为基础的回顾性研究。所有医院都参与美国外科医生质量改进项目,研究人员通过这一数据库获取接受大型腹部手术如切除胰腺,肝、胃部恶性肿瘤等患者的信息,并于201

背景
对手术病人,输血对他们而言或许具有救命的作用。然而异体输血后引起的相关免疫调节或许会增加围手术期患者死亡率增加及手术后患者预后不佳,进而影响其生存质量。 

目的
该研究的目的在于探讨重大腹部肿瘤切除术输血率的发生率对临床结果的影响。 

设计
该研究是以人群为基础的回顾性研究。所有美国医院都参与的美国外科医生质量改进项目,研究人员通过这一数据库获取接受大型腹部手术如切除胰腺,肝、胃部恶性肿瘤等患者的信息,并于2015年7月至8月进行数据分析。

主要结果和措施
研究人员重点关注输注任何数量红细胞的患者及围手术期输血率(时间范围为手术开始至手术后72小时)。次要结果包括患者出现伤口感染、心肌梗死和肾功能不全的发生率。并依据研究期间每年的数据进行趋势分析变化。 

结果
一共有19680名患者(平均年龄为65岁)参与研究,其中有5900名患者(30.0%)接受输血。在这些接受手术的患者中,有13657名患者接受了胰腺切除术,其中有4074名患者输血,占29.8%;有1605名患者接受胃部切除术,输血患者有378名,占23.6%;有4418名患者接受肝切除术,输血患者有1448名,占32.8%。研究期间,患者输血率显著降低(z = −7.89, P <0.001), 2005-2013年患者红细胞输血率降低6.1%,从32.8%降至26.7%。在研究期间术后伤口感染或肾功能不全发生率没有显著变化,但围手术期心肌梗死率增加(0.33%;z = 3.15,P =0.002)。 

结论
这项为期9年的研究表明,接受腹部肿瘤手术的患者围手术期输血率在降低。研究人员表示仍需进行更进一步的研究来评估这些趋势是否反映了手术技术的提高。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1876752, encodeId=778b18e6752ae, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 03 04:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877674, encodeId=701818e767423, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jul 04 18:59:00 CST 2016, time=2016-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686940, encodeId=250e16869401f, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Sat Apr 30 15:59:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021518, encodeId=31632021518f5, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Mar 29 15:59:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259646, encodeId=18b712596465f, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Jan 16 07:59:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1876752, encodeId=778b18e6752ae, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 03 04:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877674, encodeId=701818e767423, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jul 04 18:59:00 CST 2016, time=2016-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686940, encodeId=250e16869401f, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Sat Apr 30 15:59:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021518, encodeId=31632021518f5, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Mar 29 15:59:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259646, encodeId=18b712596465f, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Jan 16 07:59:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
    2016-07-04 chg121
  3. [GetPortalCommentsPageByObjectIdResponse(id=1876752, encodeId=778b18e6752ae, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 03 04:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877674, encodeId=701818e767423, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jul 04 18:59:00 CST 2016, time=2016-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686940, encodeId=250e16869401f, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Sat Apr 30 15:59:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021518, encodeId=31632021518f5, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Mar 29 15:59:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259646, encodeId=18b712596465f, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Jan 16 07:59:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1876752, encodeId=778b18e6752ae, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 03 04:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877674, encodeId=701818e767423, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jul 04 18:59:00 CST 2016, time=2016-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686940, encodeId=250e16869401f, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Sat Apr 30 15:59:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021518, encodeId=31632021518f5, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Mar 29 15:59:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259646, encodeId=18b712596465f, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Jan 16 07:59:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1876752, encodeId=778b18e6752ae, content=<a href='/topic/show?id=67c5319121e' target=_blank style='color:#2F92EE;'>#切除术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31912, encryptionId=67c5319121e, topicName=切除术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Sat Sep 03 04:59:00 CST 2016, time=2016-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877674, encodeId=701818e767423, content=<a href='/topic/show?id=b013169237f' target=_blank style='color:#2F92EE;'>#surgery#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16923, encryptionId=b013169237f, topicName=surgery)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7db99, createdName=chg121, createdTime=Mon Jul 04 18:59:00 CST 2016, time=2016-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686940, encodeId=250e16869401f, content=<a href='/topic/show?id=468a82841d7' target=_blank style='color:#2F92EE;'>#肿瘤切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82841, encryptionId=468a82841d7, topicName=肿瘤切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0c0b28305155, createdName=12498561m41(暂无昵称), createdTime=Sat Apr 30 15:59:00 CST 2016, time=2016-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021518, encodeId=31632021518f5, content=<a href='/topic/show?id=31e8e9669d' target=_blank style='color:#2F92EE;'>#GER#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7966, encryptionId=31e8e9669d, topicName=GER)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Mar 29 15:59:00 CST 2016, time=2016-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259646, encodeId=18b712596465f, content=<a href='/topic/show?id=569c9382389' target=_blank style='color:#2F92EE;'>#输血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93823, encryptionId=569c9382389, topicName=输血)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Sat Jan 16 07:59:00 CST 2016, time=2016-01-16, status=1, ipAttribution=)]
    2016-01-16 windight

相关资讯

JCO:中国学者提出三位一体亚肺叶切除术**指征

复旦大学附属肿瘤医院胸部肿瘤多学科综合诊治团队准确描述并定义了周围型肺腺癌的术中冰冻病理诊断,同时以此提出了兼具微创、精准和疗效三位一体亚肺叶切除手术方式的精准指征。相关成果日前在线发表于《临床肿瘤学杂志》。据上述团队首席专家陈海泉介绍,团队中的放射介入医师在CT的精确引导下,为每一例肺小结节患者通过胸外插入“带钩钢丝”,从而为外科医生术中精确找到病灶作好“位置标记”。此项技术开展近8年来,已完成

BMC Cancer:从前瞻性生物样本库到精准医学 “生物样本库-理性分子评价,创新药物筛选”-欧洲宫颈癌研究方案

摘要: 研究背景:宫颈癌是全球导致死亡的主要妇科恶性肿瘤,其死亡率仅次于乳腺癌。宫颈癌的活检组织及血液样本易于获得,对未来制定精准医学策略至关重要。 研究方案:生物样本库-理性分子评价,创新药物筛选(Biobanking-Rational molecular Assessment Innovative Drugselection BIO-RAIDs)是一项欧洲前瞻性多中心研究,目前正在欧

NEJM:肿瘤细胞耐药莫灰心,突变后可能又敏感

一旦癌症对治疗药物产生耐药性,该药物对肿瘤不再有效,医生就会换另外的药物治疗癌症,直到癌症被控制会对癌症无计可施。近期发表在NEJM上的案例报道提到一名52岁晚期肺癌患者,经治疗后的肿瘤细胞突变后对该药物具有耐药性,但却对其他药物敏感。该案例提醒医生应该对肿瘤组织重复取活检,搞清楚肿瘤细胞是如何进化演变,以及是否再次使用治疗最开始阶段使用过的药物,这些一开始治疗过的药物往往会有第二轮治疗效果。纪念

Nature:肿瘤细胞维持基因组稳定之谜破解

与正常细胞相比,癌细胞的分裂速度相当快,其基因组“质量”却相当稳定——它们是怎么做到的?丹麦哥本哈根大学Hickson教授团队与浙江大学呼吸疾病研究所沈华浩教授团队通过合作,发现肿瘤细胞在有丝分裂期存在DNA复制行为,这是肿瘤细胞维持基因组稳定性的关键。12月2日,《自然》杂志在线发表了两校教授合作完成的研究论文。共同第一作者、浙大医学院教授应颂敏说,正常细胞的分裂遵循经典的细胞分裂周期理论,在S

研究发现治疗周围型小病灶肺腺癌有效方法

河南省肿瘤医院胸外科青年医师刘士磊研究发现,术中冰冻切片的准确诊断是治疗周围型小病灶肺腺癌的有效方法,相关成果日前在线发表于《肿瘤临床学杂志》。该研究对解决肺癌治疗领域亚肺叶切除术指征的争议作出了重要探索。 早期肺癌往往表现为肺部小结节,常规肺叶切除手术常会损伤患者肺功能,采取保留肺功能的亚肺叶切除手术又很难根治,造成术后局部复发率高等“隐患”。 刘士磊发现,基于精准冰冻病理结果的

JAMA Oncology:Palbociclib或许可以治疗多种癌症

一种新的口服药物palbociclib无论是单独使用还是联合内分泌治疗,对乳腺癌均有效,除此之外也有可能治疗其他类型癌症。Palbociclib是第一个被批准用于乳腺癌治疗的CDK4 / 6抑制剂。研究者Amy S. Clark说:“所有的活细胞都在进行细胞分裂,而palbociclib具有阻止细胞分裂过程(也被称为“细胞周期”)的能力,因此具有潜在的广泛适用性。palbociclib联合其他抗癌